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Abstract
Background
The influence of factors related to the background of investigators conducting trials compar-
ing psychotherapy and pharmacotherapy has remained largely unstudied. Specializations
emphasizing biological determinants of mental disorders, like psychiatry, might favor phar-
macotherapy, while others stressing psychosocial factors, like psychology, could promote
psychotherapy. Yet financial conflict of interest (COI) could be a confounding factor as
authors with a medical specialization might receive more sponsoring from the pharmaceuti-
cal industry.
Method
We conducted a meta-analysis with subgroup and meta-regression analysis examining
whether the specialization and affiliation of trial authors were associated to outcomes in the
direct comparison of psychotherapy and pharmacotherapy for the acute treatment of
depression. Meta-regression analysis also included trial risk of bias and author conflict of
interest in relationship to the pharmaceutical industry.
Results
We included 45 trials. In half, the first author was psychologist. The last author was psychia-
trist/MD in half of the trials, and a psychologist or statistician/other technical in the rest. Most
lead authors had medical affiliations. Subgroup analysis indicated that studies with last
authors statisticians favored pharmacotherapy. Univariate analysis showed a negative rela-
tionship between the presence of statisticians and outcomes favoring psychotherapy. Multi-
variate analysis showed that trials including authors with financial COI reported findings
more favorable to pharmacotherapy.
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Discussion
We report the first detailed overview of the background of authors conducting head to head
trials for depression. Trials co-authored by statisticians appear to subtly favor pharmaco-
therapy. Receiving funding from the industry is more closely related to finding better out-
comes for the industry’s elective treatment than are factors related to authors’ background.
Limitations
For a minority of authors we could not retrieve background information. The number of trials
was insufficient to evidence subtler effects.
Introduction
Conceptual background
Two treatment alternatives dominate the field the field of mental health: psychotherapy and
pharmacotherapy. For depression, their effectiveness appears to be similar, with meta-analyses
of direct comparisons not finding any differences[1,2]. Previous analyses have mostly focused
on examining the effects of factors intrinsic to the trial, such as characteristics of the design,
participants, or interventions, on outcomes. However, the influence of factors extrinsic to the
trials, such as those related to the actual investigators conducting them has largely remained
ignored, with the notable exception of investigator funding or financial conflict of interest
(COI)[3].
These treatment alternatives are grounded in different conceptions about mental disorders.
In the oft-cited bio-psycho-social model of mental disease, psychotherapy emphasizes the psy-
chosocial component, while pharmacotherapy the biological one. The discrepancy leads to
conjectures about the individuals conducting trials confronting these treatments, and their
own preferred assumptions, which may bias them, even outside awareness, towards favoring
one type of intervention over the other. For instance, a researcher assuming that the biological
component of mental disorders is essential might unwittingly lean towards seeing medication
as a better or more necessary course of treatment. On the other hand, a researcher supposing
the psychosocial component is at the root of mental illness might be influenced towards view-
ing psychotherapy as more useful. Though it would extremely difficult to catalogue the
assumptions of all researchers conducting clinical trials, a possible proxy might be looking at
the background of trial authors, such as their specialization (i.e., academic degree) or affiliation
(i.e., the type of department in which they are professionally active). We would hypothesize
that studies where psychiatrists or other medical specializations are in lead author positions or
numerically dominate the author pool have a tendency towards finding pharmacotherapy as
more effective. Conversely, studies led or dominated by psychologists or other social scientists
might systematically find psychotherapy as more effective. Finally, we would expect trials
where lead authors are affiliated to medical departments to be partial to treatments approach-
ing mental illness as any other medical condition.
However, authors from other methodological backgrounds, such as statistics, might assume
lead positions or be well represented in the author pool. These specializations could be con-
strued as uncontaminated by assumptions regarding the primacy of biological over psychosocial
factors in mental disease, and consequently serve as a useful comparison. Recommendations
have been made that statisticians and methodologists should be systematically involved in
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research design and analysis[4], under the assumption that their presence would boost confi-
dence in the quality of the research design, analysis and reporting, and we could assume they
employ the “best” methods available. In this sense, investigating whether their presence in the
author pool might influence outcomes is particularly germane. Preliminary evidence suggests
that studies including statisticians in the research team use a common statistical test more
appropriately[5] and that fewer trials are presented as positive when statisticians are listed as co-
authors [6].
Nonetheless, some relevant confounding factors could also come into play. Authors with a
medical specialization might be more alluring to the pharmaceutical industry and subse-
quently more sponsored. In turn, this could translate into a biasing effect in favor of medica-
tion not due to specialization per se, but to side benefits from the industry (i.e., author COI).
Trial risk of bias has been consistently related to outcomes both in trials of psychotherapy and
pharmacotherapy for depression[7,8]. It is possible the effects of investigators’ preferred
assumptions about mental illness and its treatment might be more potent in trials with a
higher risk of bias[9].
We were unable to find any previous studies examining whether the background of authors
conducting clinical trials that directly compare psychotherapy and pharmacotherapy might
have a systematic effect on outcomes. Also, while trials are usually conducted by an assortment
of investigators of different backgrounds, we could not retrieve any literature on the composi-
tion of this mix or the proportion with which certain fields were represented.
Study objectives
The first goal was to provide an overview regarding the specialization and affiliation of authors
of trials comparing psychotherapy and pharmacotherapy for depression, as well as of the pro-
portions with which medical, social science and statistical/technical academic fields were rep-
resented. The second objective involved examining whether these background variables, both
applied to the lead authors of the report describing a trial and to the composition of the author
pool, could systematically bias the results of the comparison between these two treatments.
Method
Identification and selection of studies
Studies were selected from a database of papers on the psychological treatment of depression
described in detail elsewhere[10] and that has been used in a series of earlier published meta-
analyses (www.evidencebasedpsychotherapies.org). This database is updated at the beginning
of each year through comprehensive literature searches. In these searches, abstracts from
Pubmed, PsycInfo, Embase and the Cochrane Register of Trials were identified by combining
search terms indicative of psychological treatment or psychotherapy and depression (both
MeSH terms and text words). The exact search string for Pubmed is provided in S1 File. For
this database, primary studies from earlier meta-analyses of psychological treatment for
depression were also checked to ensure that no published studies were missed. For this analy-
sis, we used the available version of the database covering studies published between 1966 to
January 2015. Two researchers independently performed the selection of the studies from the
database.
We included (a) randomized trials (b) in which the effects of a psychotherapy (c) was
directly compared with the effects of antidepressant medication (d) in adults (e) with a depres-
sive disorder for outcomes (f) measured on validated symptom scales or diagnostic instru-
ments for depression. All forms of psychotherapy, regardless of their type (e.g., cognitive
behavioral therapy, interpersonal therapy), format (individual, group), intensity or duration
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were included, as well as all forms of antidepressant medication, regardless of their type (e.g.,
tricyclics, SSRIs), dose or duration of treatment. We excluded augmentation studies in which
medication or psychotherapy were combined and compared to one treatment, due to the
impossibility of disentangling the effects of psychotherapy and pharmacotherapy in these tri-
als. We also excluded maintenance or continuation studies, focused on patients who had fully
or partially recovered from an earlier treatment, again because these trials included add-on
effects of psychotherapy and medication. Studies on inpatients were also excluded due to the
particular constraints imposed by this setting and the fact that inpatients are medicated most
of the time. However, studies where participants had other comorbid mental or somatic disor-
ders in addition to depression were included.
There was no registered protocol for the present systematic review.
Risk of bias (RoB) assessment and data extraction
Assessment of risk of bias. As described in a previous paper[3], trial RoB was rated using
four criteria of the Cochrane Collaboration[11] assessment tool: adequate generation of alloca-
tion sequence; concealment of allocation to conditions; the prevention of knowledge of the
allocated intervention (blinding of assessors); and dealing with incomplete outcome data.
Blinding of assessors was rated as low risk if the trial described proper methods of ensuring it
or if all relevant outcome measures were self-report, thus not requiring the direct interaction
with an assessor. Dealing with incomplete outcome was rated as low risk when intent-to-treat
(ITT) analyses, including all randomized patients were conducted, regardless of their subse-
quent initiation of or participation in treatment. All methods of conducting ITT that included
all randomized participants were considered valid, as the Cochrane Collaboration does not
make any specific recommendations and many of the trials predate recent discussions regard-
ing the validity of certain methods of handling missing data[12,13]. We also computed a “risk
of bias” score for each study, by giving one point to each domain for which a study could be
rated as low RoB.
Extraction and coding of moderators. As we were unable to find any published literature
looking at author specialization, we constructed an operational definition. Author specializa-
tion was defined as the academic field in which the person had graduated or been qualified in
and was evaluated for each of the authors of the report. However, since in many cases authors
have a rich and diverse training, we were constrained to operate with a number of coding deci-
sions that sacrificed granularity. Specialization was coded in the following categories: psychia-
try/other medical degree (MDs); psychologist/other social science (e.g., Social Work);
Statistics/Epidemiologist/other “purely” technical professions (e.g., Physics, Engineering).
Medical doctors were always considered in the first category, even if they had a subsequent
advanced degree in another field, like Psychology. This decision was based on several consider-
ations. First, a degree in Medicine is an advanced degree associated with cultural assumptions
of intellectual prestige (justified or not), as proven by the fact medical doctors almost never fail
to include this title (“MD”) together with their name, regardless of whether or not they have
obtained additional degrees afterwards. Secondly, this information is certain and lends itself to
independent verification as it almost invariably reported by authors. This renders its coding
less subjective and more reproducible. For authors who were not MDs, in the case of multiple
post-graduate degrees, we considered the one that fit into one of the remaining categories: psy-
chologist/other social science and statistics/epidemiology/other “technical”. In the case in
which the authors had multiple degrees, which did not fit exactly fit in any of our categories,
the clearest fit to our classification (usually, the first or undergraduate degree) was considered.
It should also be noted that due to the diversity of several graduate and post-graduate
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specializations, these are often harder to classify and information is often times missing about
the academic concentration of these programs. For instance, a person with a degree in Psy-
chology and graduate studies in Neuroscience was classified in the psychologist/other social
science category. However, depending on the particular program concentration, an advanced
degree in Neuroscience could also be considered more medical. Thus, using the graduate
degree would have been made the classification of this particular author difficult.
Some types of degrees were considered exceptions and were not counted in any of these cat-
egories. Based on our familiarity with the literature on psychotherapies for depression, we
anticipated a priori that some authors would be trained as nurses and, respectively, economists.
While nursing could be seen as a medical degree, nurses are also often trained in psychother-
apy[14] and in charge of delivering it in the trial, while medication is still delivered by a psychi-
atrist. Moreover, different academic systems have different frameworks for education in
Nursing, with it being incorporated within the faculty of Medicine in some cases, and it being
an independent, stand-alone faculty in others. Consequently, it becomes difficult to establish
whether they would, by virtue of their specialization, be more partial to pharmacotherapy or,
on the contrary, given their training and role in the trial, to psychotherapy. Biomedical special-
izations, such as pharmacology, were also difficult to classify and excluded from the classifica-
tion. These specialists are usually not involved in patient interaction and as such it is unclear
whether they would hold a priori assumptions about what component (biological or psychoso-
cial) might be more relevant in treatment. Finally, we also did not include degrees in economy
in the analysis, since economists do not acquire specialized knowledge about mental disease
and its treatment and do not have patient contact. A case could be made for including them in
the technical category, but we were worried this might become too heterogeneous if it com-
bined so many different specializations.
The process of extracting information about author specialization followed a sequential
decision tree approach, schematically represented in Fig 1. In this process priority was given to
the specialization with which the authors themselves identified, since we primarily considered
author reported information present in the main paper or in other co-authored works (articles,
books).
We first examined what was reported in the article, as it is the practice of some journals to
also list the authors’ academic specialization (e.g., The BMJ, British Journal of Psychiatry). If
this information was not available, we looked for other articles or book chapters and prefaces
by the same author published around the same period (2 years before and after). This choice
was made as particularly books include a brief author description usually written by the author
herself. Next, we looked as to whether the original article or other articles in the same period
included other relevant information, such as affiliations to professional boards like the Royal
College of Psychiatrists. In these cases, we checked if the rules of the professional board
imposed that members hold a particular type of degree (usually an MD degree for medical pro-
fessional boards). If we still had not managed to retrieve the information about a particular
author’s specialization, we subsequently proceeded to search each author from the report
using the search engine Google. We primarily looked for personal or institutional web pages
(e.g., university, hospital) or bio sketches available online, as in most cases these include the
authors’ educational background. If these were not available, we passed to social network pro-
files listing academic preparation (e.g., Linkedin, Researchgate), professional databases (e.g.,
Healthgrades), as well as verified websites that aggregate existent data into professional profiles
(www.zoominfo.com). Finally, if no information was available through these extensive internet
searches, the corresponding author of the paper was contacted or, if this author was unavail-
able (usually in the case of old papers), other researchers that were frequent co-authors. The
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authors for whom we did not manage to find information through any of these methods were
excluded from the analyses.
Author affiliation was defined as the department in which the author was professionally
active (e.g., psychology, psychiatry), regardless of the larger institutional context in which the
department was inserted (e.g., medical hospital, national research institution). In the infre-
quent cases in which the author was not affiliated with a department, the closest similar formal
group (e.g., research center, institute) was considered. Affiliation was coded was medical
(referring to any medical or biomedical department or similar institute, including but not
Fig 1. Search and extraction of information about author specialization: Sequential decision tree.
doi:10.1371/journal.pone.0171654.g001
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restricted to psychiatry); non-medical (referring to any type of non-medical department,
including psychology, other social sciences or technical departments). In the case of multiple
affiliations, priority was given to the medical ones, as with specialization. This coding decision
was made because medical affiliations constituted the largest portion of our sample and thus
represented a more homogenous category. In contrast, the non-medical category included a
vast array of affiliations and research areas. Information about the affiliation was extracted
from the reports, as were interested at the authors’ affiliation at the time the trial was con-
ducted and published.
Data regarding specialization and affiliation was organized in a number of categorical and
continuous variables both regarding lead authors (first and last) and the composition of the
author pool:
1. Specialization of the first and respectively last author;
2. Affiliation of the first and last author;
3. The proportions, expressed in percentages, from the total number of authors of a trial for:
psychologists; social scientists (psychologists plus other degrees); psychiatrists; MDs (psy-
chiatrists plus other MDs) and respectively, statisticians/epidemiologists/other technical
specialty.
4. The ratio of the number of psychologists to the number of psychiatrists, and respectively
social scientists to MDs.
We also coded author financial conflict of interest (COI), in order to include in multivariate
analyses. Author COI was the subject of a more detailed previous analysis on this dataset,
which includes more extensive information about its evaluation[3]. Briefly put, it was defined
as the receipt of financial support or benefits of any type from the industry. Information about
COI was extracted primarily from the articles included in the meta-analysis, but also from
other reports co-authored by the same individuals and originating in the same time frame.
This variable was coded dichotomically for each trial into: yes (at least one of the authors of the
report has COI) and not reported (no information about COI). We did not include a separate
category of no COI (i.e., authors having declared not having any COI) because our previous
analysis on these trials showed these declarations can often be inaccurate[3]. In it, we identified
instances in which one or more of the authors of the original article had a financial COI and
had not reported it in the main article. Moreover, the number of cases in which the authors
explicitly declared not having any financial COI was very small.
Data regarding specialization, affiliation, and author COI was extracted from the papers
and the additional resources described above by one researcher. Subsequently, a third of the
included papers was randomly chosen (using a random number generator) for independent
evaluation by another researcher, who did not have access to the data extracted by the first.
Risk of bias ratings were carried out by two independent researchers. Disagreements were
resolved through discussion.
Meta-analysis
Effect size calculation. We calculated and pooled the individual effect sizes with the com-
puter program Comprehensive Meta-analysis (CMA; version 3.3.070), using a random effects
meta-analysis. For each comparison between psychotherapy and pharmacotherapy, an effect
size (ES) indicating the difference between the two groups at post-test (Hedges’ g) was calcu-
lated by subtracting the mean of the pharmacotherapy group from the mean of the psychother-
apy group, dividing the result by the pooled standard deviation, and correcting for small
Meta-analysis of investigator background in relationship to treatment outcome in depression trials
PLOS ONE | DOI:10.1371/journal.pone.0171654 February 3, 2017 7 / 18
sample bias[15]. In the cases where a study included more than one comparison between a
form of psychotherapy and a drug, we averaged comparisons at study level employing the pro-
cedures implemented in CMA[16]. Sensitivity analyses were also conducted using only the
comparisons with the ES most favourable to psychotherapy and, respectively, pharmacother-
apy. For the studies that only reported data in subgroups (and not for the overall psychother-
apy or pharmacotherapy group), subgroups were averaged at the study level. Outcomes were
considered only if they were measured with instruments explicitly validated for depressive
symptoms, such as Hamilton Rating Scale for Depression (HAM-D) or the Beck Depression
Inventory (BDI). For studies where means and standard deviations were not reported and
could not be obtained from the authors, we transformed dichotomous data into the standard-
ized mean difference using the formulas implemented in CMA[16] or used other statistics,
such as t-values or exact p-values to calculated the standardized mean difference. We calcu-
lated the I2-statistic as an indicator of heterogeneity in percentages. A value of 0% indicates no
observed heterogeneity, while larger values indicate increasing heterogeneity, with 25% as low,
50% as moderate, and 75% as high heterogeneity[17]. We calculated 95% confidence intervals
(CIs) around I2 [18], using the non-central χ2-based approach with the heterogi module for
STATA[19]. Outliers were defined as ESs for which the 95% CI was outside the 95% CI of the
pooled studies.
Publication bias. Publication bias was assessed in three ways: 1) visual inspection of the
asymmetry of the funnel plot; 2) the Duval-Tweedie trim and fill procedure[20] (as imple-
mented in CMA, version 3.3.070, searching for missing studies left of the mean using a fixed
effects model), which provides an adjusted effect size after the publication bias has been taken
into account and also indicates how many studies were imputed to correct for publication
bias; and 3) Egger’s test of the intercept to test the symmetry of the funnel plot[21].
Subgroup and meta-regression analysis. The focus on our analysis was on subgroup and
meta-regression analysis. For subgroup analyses, we used a mixed effects model[16] to test
whether there were differences among studies regarding first and last author specialization
and affiliation (coded categorically). We conducted both univariate and multivariate analyses
using the same program, CMA version 3.3.070. Meta-regression analyses were conducted
according to a random effects model using the Knapp-Hartung method. Univariate analyses
were conducted separately for variables regarding the percentage of social scientists, MDs, and
respectively, statisticians /epidemiologist/other technical specialty from the total number of
authors. To reduce the number of statistical tests we only used the most inclusive category (i.e.,
social scientists and respectively MDs). The ratio of psychologists to psychiatrists, or social sci-
entists to MDs, was not used in subgroup and meta-regression analyses. This was due to the
fact that in part this variable duplicated information already existent in other indexes consid-
ered (i.e., proportion of psychologists or psychiatrists) and also to its highly skewed distribu-
tion, with extreme values at both ends. This asymmetry raised doubts about the stability of any
results using this variable, as they could be driven by extreme values.
Multivariate analysis included specialization and affiliation as predictors of interest,
together with RoB score and author COI. Categorical variables were dummy coded for use in
multivariate analysis, with one category being used as the reference category. The medical cate-
gory was used as the reference category for both specialization and affiliation, as it was con-
structed based on the most certain, reliable information, and because the contrast with
medical specializations and affiliations was one of our main points of interest.
In order to avoid collinearity, for variables that correlated with an r greater than 0.50, we
just included one in the analyses. Prior to conducting multivariate analysis, we computed cor-
relations between predictors of interest. Multivariate analysis also included the more inclusive
categories of percentages of authors social scientists, and respectively MDs.
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Results
Selection and inclusion of studies
A total of 16,365 abstracts (12,196 after removal of duplicates) was examined and 1,756 full-
text papers were retrieved for detailed consideration. The PRISMA flowchart describing the
inclusion process is presented in Fig 2. We excluded 1,711 records from the retrieved papers
(reasons given in the flowchart). Forty-five trials met the inclusion criteria (full study list in
S2 File). Out of these, nine included 2 comparisons between a form of psychotherapy and
medication.
Characteristics of the included studies
Selected characteristics of included studies focused on the variables of interest are present in
Table 1. We note that a more detailed description of included studies in terms of participants,
interventions and other trial features can be found in previous papers on this database[1].
The first author was a psychologist or social scientist in 20 studies (in 19 cases with a degree
in psychology, in one with a degree in social work), a psychiatrist or MD in 23 studies (17 psy-
chiatrists and 6 other MDs) and a nurse in 2 studies. The last author was a psychologist in 9
studies, an economist in 1, a psychiatrist in 15, an MD of another kind in 9, a statistician/ epi-
demiologist/other technical in 9 studies. For 2 studies we could not retrieve information about
the last author. Affiliation was mostly medical both for the first author (34 trials) and for the
last author (37 trials). The composition of the author pool was variable. Three reports were
authored exclusively by psychologists, and 10 included no psychologists at all. In the remaining
trials, the ratio of psychologists to psychiatrists ranged from 0.2 to 11, and 9 studies had three
Fig 2. Flowchart of selection and inclusion process, following the PRISMA statement.
doi:10.1371/journal.pone.0171654.g002
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Table 1. Selected characteristics of studies directly comparing psychotherapy and pharmacotherapy for adult depression.
Study 1st AU
Spec
1st AU
Affil
Last AU
Spec
Last AU
Affil
%
Psychol
%Soc
Sci
%
Psyc
%
MD
%Stat/
Techn
Psychol/
Psych
Soc Sci/
MD
COI RoBa)
SG AG BA
ITT
Barber, 2011 Psychol Med Psych Med 40 40 40 40 20 1 1 Y + ? + +
Barrett, 2001 Psych Med Stat Med 33 33 22 56 11 1.5 0.6 Y + ? + −
Bedi, 2000 Psych Med MD Med 0 0 36 55 27 0 0 NR ? + SR −
Blackburn, 1997 Psychol Non-
med
Psychol Non-
med
100 100 0 0 0 Indet Indet NR ? ? + −
Blom, 2007 Psych Med Psych Med 29 29 43 43 14 0.6 0.6 NR ? ? + −
Browne, 2002 Nurse Non-
med
MD Med 0 0 0 55 0 0 0 NR + + + −
David, 2008 Psychol Non-
med
Psych Med 50 50 50 50 0 1 1 NR ? ? + +
Dekker, 2008 Psychol Non-
med
Psych Med 44 44 56 56 0 0.8 0.8 NR ? ? + −
DeRubeis, 2005 Psychol Non-
med
Stat Non-
med
55 55 36 36 9 1.5 1.5 NR ? ? + +
Dimidjian, 2006 Psychol Non-
med
Psychol Non-
med
85 85 8 8 8 11 11 Y + − + +
Dunlop, 2012 Psych Med MD Med 50 50 17 33 17 3 1.5 Y ? + + −
Dunner, 1996 Psych Med NI Med 50 50 33 33 0 1.5 1.5 NR ? ? + −
Elkin, 1989 Psychol Non-
med
Psychol Non-
med
67 67 25 25 8 2.6 2.6 NR + ? + −
Faramarzi, 2008 Psychol Med NI Med 50 50 17 33 0 3 1.5 NR ? ? SR −
Finkenzeller,
2009
MD Med Psych Med 40 40 20 60 0 2 0.7 NR + ? + +
Frank, 2011 Psychol Med Econ Med 13 13 40 40 33 0.3 0.3 Y − − + +
Hegerl, 2010 Psych Med Psych Med 56 56 33 44 0 1.7 1.2 Y + + + +
Hollon, 1992 Psychol Non-
med
Psych Med 71 71 29 29 0 2.5 2.5 NR ? ? + +
Jarrett, 1999 Psychol Med Stat Med 50 50 17 17 33 3 3 NR ? + + +
Keller, 2000 Psych Med Psych Med 25 25 67 75 0 0.4 0.3 Y + + + −
Kennedy, 2007 Psych Med MD Med 43 43 29 43 0 1.5 1 Y ? ? ? −
Markowitz, 2005 Psych Med Psych Med 20 20 60 60 20 0.3 0.3 Y + − + +
Martin, 2001 Psych Med Eng Med 0 0 40 40 40 0 0 Y − − − +
McKnight, 1992 Psychol Med Psych Med 67 67 33 33 0 2 2 NR ? ? ? −
McLean, 1979 Psychol Med Psychol Non-
med
100 100 0 0 0 Indet Indet NR ? ? SR −
Menchetti, 2014 Psych Med Psych Med 0 0 71 71 29 0 0 Y + + ? +
Miranda, 2003 Psychol Med Stat Non-
med
57 57 14 14 29 4 4 NR + + + +
Mohr, 2001 Psychol Med Psych Med 40 40 20 40 20 2 1 NR − − − +
Moradvesi, 2013 Psychol Non-
med
Psychol Non-
med
80 80 20 20 0 4 4 NR + + + +
Murphy, 1984 Psych Med Psychol Med 75 75 25 25 0 3 3 NR − − − −
Mynors-Wallis,
1995
Psych Med MD Med 0 0 50 100 0 0 0 NR ? + + −
Mynors-Wallis,
2000
Psych Med MD Med 0 0 50 75 0 0 0 NR + + + +
Parker, 2013 Psych Med Psychol Med 64 64 27 27 0 2.3 2.3 Y + + + −
Quilty, 2008 Psychol Med Psychol Med 100 100 0 0 0 Indet Indet NR ? ? ? −
Rush, 1977 Psych Med Psychol Med 50 50 50 50 0 1 1 NR ? ? + −
(Continued )
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times more psychologists than psychiatrists. Twenty-four studies included no authors from
the category statisticians/epidemiologists/other technical. Author COI was present in 15 trials,
while for the other 30 it was not reported and we could not uncover additional information
pointing to it.
Meta-analysis
Publication bias. Similar to what was reported in a previous papers[3] on this database of
trials and the comparison between psychotherapy and pharmacotherapy, there was evidence
of publication bias in the visual inspection of the funnel plot. The Duval-Tweedie trim and fill
procedure imputed 6 studies, leading to a pooled ES more favorable to pharmacotherapy but
still not significant, g = -0.11, 95% CI -0.22 to 0.003. However, Egger’s test did not indicate a
significant asymmetry of the funnel plot (intercept = 0.91, 95% CI -0.34 to 2.16).
Subgroup analyses. Subgroup analyses (Table 2) indicated a significant difference for the
specialization of the last author (p = 0.002). Specifically, studies where the last author was clas-
sified as statistician/epidemiologist/other technical found a small statistically significant
advantage of pharmacotherapy over psychotherapy (g = -0.25, 95% CI -0.37 to -0.14). Studies
where the last author was either psychologist/social scientist or psychiatrist/MD did not find
significant differences between the two treatments. To further explore this effect, we also classi-
fied the proportion (expressed as percentages) of statisticians/epidemiologists/other technical
from the total author pool in: none; over 0 and under 20%; 20% or more. There were signifi-
cant differences between these 3 subgroups (p = 0.031). Trials with at least one author but less
than 20% from this category resulted in a pooled ES favoring pharmacotherapy over psycho-
therapy (g = -0.14, 95% CI -0.26 to -0.01). Differences between the two treatments were not
Table 1. (Continued)
Study 1st AU
Spec
1st AU
Affil
Last AU
Spec
Last AU
Affil
%
Psychol
%Soc
Sci
%
Psyc
%
MD
%Stat/
Techn
Psychol/
Psych
Soc Sci/
MD
COI RoBa)
SG AG BA
ITT
Salminen, 2008 MD Non-
med
Stat Non-
med
13 13 63 75 13 0.2 0.1 Y ? ? − +
Schulberg, 1996 Psychol Med MD Med 20 30 10 40 10 2 0.7 NR ? ? + +
Scott, 1992 Psych Med Psych Med 0 0 100 100 0 0 0 NR ? + + −
Shamsaei, 2008 Nurse Med Stat Med 25 25 25 25 25 1 1 NR ? + SR ?
Sharp, 2010 MD Med Stat Med 0 0 33 58 8 0 0 Y + + + +
Sloane, 1985 MD NI Psych NI 33 33 67 67 0 0.5 0.5 NR − − + −
Thompson,
2001
Psychol Med MD Med 60 60 20 40 0 3 1.5 NR ? ? ? −
Weissman, 1979 Soc work Med Psych Med 0 17 67 67 0 0 0.2 NR ? ? + −
Williams, 2000 MD Med Stat Med 38 38 13 50 13 3 0.7 Y + + + +
Zu, 2014 MD Med MD Med 0 0 15 85 0 0 0 NR + ? + −
Note.
a) RoB: risk of bias according to the Cochrane Collaboration tool. SG, sequence generation; AC, allocation concealment; BA; blinding of assessors; ITT,
intent-to-treat analysis to handle missing data. Ratings of “+” indicate the study has a low RoB on that criteria; ratings of “-”indicate high RoB; “?” uncertain
RoB; SR, only self-report measures
Abbreviations: Affil, Affiliation; AU, Author; COI, Conflict of interest; Econ, Economist; Eng, Engineer; Indet, Indeterminate; MD, Medical doctor; Med,
Medical; NI, no information; Non-med, Non-medical; NR, not reported; Psych, Psychiatrist; Psychol, Psychologist; Spec, specialization; Soc Sci, Social
scientist; Soc work, Social work; Stat, Statistician; Techn, Technical; Y, yes.
doi:10.1371/journal.pone.0171654.t001
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significant in studies with more than 20% of authors from this category. No other subgroup
comparisons were statistically significant.
Univariate meta-regression. Univariate analysis (Table 2) indicated a significant negative
relationship between the proportion (expressed as percentages out of the total number of
authors) of authors statisticians/epidemiologists/other technical and outcomes in favor of psy-
chotherapy (slope coefficient b = -0.01, 95% CI -0.02 to -0.0004, p = 0.041). In other words, an
increase in the proportion of authors from this category was associated with better outcomes
for pharmacotherapy over psychotherapy. The relationships between the proportion of psy-
chologists/social scientists, and respectively psychiatrists/MDs, with depression outcomes
were not significant.
Multivariate meta-regression. We examined two multivariate models, both detailed in
Table 3. First author specialization was dummy coded into one variable examining the contrast
Table 2. Effects of studies comparing psychotherapy and pharmacotherapy for adult depressiona.
Variable ncomp g 95% CI I2 I2 95% CI pb Slope 95% CI p
Depression 45 -0.02 -0.12~0.07 58 38~69
One ES per study (most favourable to psychotherapy) c 45 -0.003 -0.10~0.10 60 42~71
One ES per study (most favourable to pharmacotherapy) c 45 -0.04 -0.14~0.06 57 38~69
Outliers removedd 41 -0.07 -0.14~0.004 22 0~47
Subgroup analysise
1st Author Specialization: Psychologist/Social scientist 20 0.009 -0.15~0.16 63 34~76 0.07
Psychiatrist/MD 23 -0.01 -0.15~0.12 53 1~66
Nurse 2 -0.31 -0.55~-0.07 0 n/af
1st Author Affiliationg: Non-medical 10 -0.005 -0.23~0.22 67 23~82 0.85
Medical 34 -0.03 -0.14~0.08 56 32~70
Last Author Specializationh: Psychologist/Social scientist 8 0.12 -0.17~0.40 60 0~80 0.002
Psychiatrist/MD 25 0.02 -0.10~0.15 52 15~68
Statistician/Technical 9 -0.25 -0.37~-0.14 0 0~54
Last Author Affiliationg: Non-medical 7 0.07 -0.24~0.38 76 38~87 0.49
Medical 37 -0.04 -0.15~0.06 54 28~67
Proportion of statisticians: None 24 0.11 -0.05~0.27 64 39~76 0.031
> 0 and < 20% 11 -0.14 -0.26~-0.01 22 0~66
20% or more 10 -0.17 -0.05~0.27 53 0~75
% Social Scientists 0.002 -0.002~0.006 0.30
% MDs 0.001 -0.004~0.006 0.63
% Statisticians/Technical -0.01 -0.02~-0.0004 0.041
Note.
a All results are reported with Hedges g, using a random effects model. A positive effect indicates superiority of psychotherapy.
b The p levels in this column indicate whether the difference between the ESs in the subgroups is significant (significant results are marked with bold)
c Studies with more than one comparison: David, 2008; Dimidjian, 2006; Elkin, 1989; Markowitz, 2005; McLean, 1979; Mohr, 2001; Mynor-Wallis, 2000;
Quilty, 2008; Scott, 1992.
d Outliers were defined as studies in which the 95% CI was outside the 95% CI of the pooled studies. Above the 95% CI (favoring psychotherapy):
Faramarzi, 2008; Moradveisi, 2013; Rush, 1977. Below the 95% CI (favoring pharmacotherapy): Sharp, 2010
e Subgroup analysis were conducted using a mixed effects model.
f Confidence intervals around I2 cannot be calculated if there are less than 3 groups
g Sloane et al., 1985 did not report information on the affiliation of the author
h We were unable to retrieve information about the specialization of the last author of Dunner et al., 1996 and Faramarzi et al., 2008. In another study (Frank
et al., 2011), the last author was an economist
doi:10.1371/journal.pone.0171654.t002
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between psychologists/social scientists and psychiatrists/MDs. Last author specialization was
coded into two dummy variables, corresponding to the contracts between psychologists/social
sciences and respectively statisticians/technical as contrasted to psychiatrists/MDs. Affiliation
was dummy coded into medical versus non-medical, and author financial COI into existent
versus not reported.
Some variables were found to be strongly correlated with each other, and thus we ran sepa-
rate analyses in which only one was retained. The affiliation of the 1st author correlated with
that of the last author (r = 0.59). The percentage of psychologists/social scientists had correla-
tions that exceeded our threshold with the specialization of the 1st author (r = 0.55), the per-
centage of psychiatrists/MDs (r = -0.78) and with one of the dummy variables for last author
specialization that contrasted authors psychologists/social scientists with authors statisticians/
other technical (r = 0.66). Additionally, the percentage of author psychiatrists/MDs also had
correlations larger than 0.5 with the specialization of the 1st author (r = -0.57), as well as with
the same dummy variables for last author specialization (r = -0.51). The percentage of statisti-
cians/other technical was also correlated with the other dummy variable for last author special-
ization (r = 0.57). Neither risk of bias nor author COI displayed correlations over 0.50 with
any of the variables considered. To tackle with the high correlations between some of our pre-
dictors of interest, we analyzed two multivariate models: (a) including only last author affilia-
tion, 1st and respectively last author specialization, along with RoB and author COI; (b)
including only last author affiliation, percentage of psychiatrists/MDs, and percentage of statis-
ticians/other technical, along with RoB and author COI.
In model a that included 1st and last author specialization and affiliation, we found author
financial COI to be a significant predictor (b = -0.27, 95% CI -0.53 to -0.01, p = 0.04). How-
ever, we found a close to significance trend for trials where the first author was a psychologist/
social scientist to report more favorable outcomes for pharmacotherapy than studies where the
first author was a psychiatrist/MD (b = -0.25, 95% CI -.51 to 0.01, p = 0.06). In a similar vein,
Table 3. Multivariate meta-regression analyses with all moderators of interest.
Depression (all outcomes) Multivariate: Full model
Coeff 95% CI p a)
Model a
RoB 0.05 -0.04~0.15 0.25
1st Author Specialization Psychologist/Social scientist vs Psychiatrist/MD -0.25 -0.51~0.01 0.06
Last author Specialization: Psychologist/Social scientist vs Psychiatrist/MD 0.21 -0.10~0.52 0.17
Last Author Specialization: Statistician/Technical vs Psychiatrist/MD -0.26 -0.53~0.01 0.06
Last Author Affiliation: Non-medical vs Medical 0.13 -0.20~0.47 0.43
Author Financial COI: Present vs Not reported -0.27 -0.53~-0.01 0.04
Model b
RoB 0.008 -0.09~0.11 0.87
Last Author Affiliation: Non-medical vs Medical 0.13 -0.19~0.45 0.42
% MDs 0.002 -0.003~0.007 0.44
% Statistician/Technical -0.008 -0.02~0.003 0.14
Author Financial COI: Present vs not reported -0.15 -0.41~0.10 0.24
Note.
a) The p levels in this column indicate whether the relationship between the moderator and effects sizes is significant in meta-regression analyses
(significant results are in bold). Positive coefficients indicate a superiority of psychotherapy.
Coeff, Coefficient; MD, Medical doctor; COI, conflict of interest
doi:10.1371/journal.pone.0171654.t003
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trials where the last author was a statistician/other technical as contrasted to those where he/
she was a psychiatrist/MD showed a borderline significant trend of favoring pharmacotherapy
(b = -0.26, 95% CI -0.53 to 0.01, p = 0.06). In model b, which included the proportions of MDs
and authors statisticians/other technical, none of the predictors were significantly related to
outcomes.
Discussion
Summary of main results
Our investigation was based on the notion that the principal treatments for mental disorders
-psychotherapy and pharmacotherapy- are grounded in different conceptions of what causes
mental disease and which components should be at the center of treatment. Based on this dis-
tinction, we queried whether the preferred assumptions of investigators conducting trials com-
paring these two treatments might bias them, even unwittingly, towards one intervention or
another. We conjectured the background of trial authors, as reflected in their specialization
and affiliation, might function as a proxy for these assumptions.
The first goal of our study was to provide a more detailed overview regarding the back-
ground of investigators who conducted the studies confronting these two treatments for
depression. These aspects have remained largely unknown and indeed not considered so far.
For the lead authors, our results showed a balanced situation for the specialization of the first
author, with about half of the studies having a psychologist and the other a psychiatrist/MD in
this position. However, the majority (roughly half) of studies had an author who was a psychia-
trist/MD as the last author, with the other half equally split between an investigator psycholo-
gist/social scientist or statistician/other technical. Lead authors mostly came from medical
settings. The composition of the author pool was variable, but an interesting aspect was the
fact that about a half of the studies also had authors from the statistics/epidemiology/other
technical category. At a descriptive level, our results offer a useful inventory of the background
of investigators of head to head trials of psychotherapy and pharmacotherapy for depression
and could be used as a starting point in other studies.
Our second objective was examining potential systematic associations between these back-
ground variables and depression outcomes. Subgroup and univariate analyses consistently
revealed a pattern regarding authors that were statistician/epidemiologists/other technical pro-
fessions. Studies in which these authors were in lead positions (last authors) found significantly
more favorable results for pharmacotherapy. Also, when looking at the proportion of authors
in this category from the total author pool, univariate meta-regression indicated that an
increase in this proportion was also associated with better outcomes for pharmacotherapy. In
the same vein, subgroup analyses indicated significant differences between studies with vary-
ing proportions of authors statisticians/epidemiologists/other technical. More exactly, studies
with at least one but less than one fifth of the investigators from this category found more
favorable results for pharmacotherapy. Multivariate analysis also showed a borderline signifi-
cant trend of studies finding more favorable outcomes for pharmacotherapy when the last
author was a statistician/other technical as compared to a psychiatrist/MD.
Implications
We presumed the category of statisticians to be less contaminated by assumptions regarding
the primate of biological or psychosocial factors in mental diseases and their treatments. We
cited previous evidence in this sense, showing that the presence of statisticians in the author
pool is associated with a more appropriate use of a standard statistical test[5] and with less
reporting of trials as positive[6]. However, both cited studies used methods of assessing author
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background that were very different from ours. In the first[5], the authors used a rather crude
method of individuating statisticians, considering as such any authors listed as members of
departments of statistics, clinical epidemiology and related disciplines, as well as any authors
credited for statistical review in the analyses. In comparison, the method we employed brings
additional precision and reliability as we checked every individual author. In the other analysis
[6], the authors accounted for the presence of statisticians in the author pool by surveying the
corresponding author of the trial. This method also has several limitations, as authors might
be biased toward reporting that statisticians were present, could use different definitions of
statisticians, equate a wide range of specializations with statisticians or conflate proper training
with short courses or being an expert by virtue of practice.
One interesting finding that emerged from our analysis was that trials where these authors
are better represented or take leading positions arrive to results favoring pharmacotherapy.
We can only speculate on the reasons for these results. For instance, since psychologists and
social scientists in general usually also receive training in statistics and are more confident in
analyzing data, it is conceivable trials where they are dominant don’t usually see the need for
statisticians. On the other hand, studies more dominated by the medical profession might be
more keen to having statisticians or other such professions on board. However, it is worth not-
ing that the effect was small in magnitude and only borderline significant in multivariate anal-
ysis. Given that the presence of statisticians or other such professions could be viewed as
providing additional reassurance in the quality of data analysis, with recommendations having
been made in this sense[4], these results may imply that pharmacotherapy has somewhat better
outcomes than psychotherapy. This idea is also consistent with the fact that adjustment for
publication bias shifted the pooled comparative effect size as more favorable to pharmacother-
apy than psychotherapy (albeit still non-significant). Yet it is also very well possible these may
describe spurious findings, especially since in the multivariate analyses most of these variables
were not consistently significant anymore.
For multivariate analyses, given that many of our variables of interest were correlated and
their use in the same analysis would have provided biased estimated, we tested two separate
models. In the first, we only included affiliation and specialization, while in the second we
focused on the proportion of authors MDs and respectively statisticians. In the first model, we
found that only author financial COI, defined as authors’ financial ties with the pharmaceutical
industry, to be a significant predictor of outcome. Its presence was unsurprisingly associated
with better outcomes for pharmacotherapy. We note that this factor was also the subject of a
previous more detailed investigation focused on sponsorship bias[3], where we did not con-
sider author background variables, but showed the same trend of studies authored by research-
ers financially supported by the industry to favoring pharmacotherapy over psychotherapy. In
the present analysis, author COI remained a significant predictor even when other variables
regarding the specialization and affiliation of study authors were taken into account. We
hypothesized that, as investigators, MDs in general and psychiatrists in particular might be
more alluring to the pharmaceutical industry and hence benefit from more sponsorship. Con-
sequently, it would seem that receiving funding from the industry is more closely related to
finding better outcomes for the industry’s elective treatment than factors having to do with the
author background. However, we note that in the second model, where we considered propor-
tions of authors with a psychiatry/MD or statistical/technical specialization, author financial
COI was no longer a significant predictor of outcome.
Regarding background variables, the specialization of the first author and respectively last
author both came close to statistical significance in the first model. Studies in which the first
author was psychologist/social scientist as compared to psychiatrist/MD, and respectively
studies where the last author came from the statistical/technical category as compared to a
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psychiatrist/MD showed a non-significant trend favoring pharmacotherapy over psychother-
apy. We note that the first author was a non-psychologist social scientist in only one case, so
this result could be construed as referring to the comparison between psychologists and medi-
cal doctors. Assuming that psychologists would be inclined, by virtue of training, to view psy-
cho-social factors as essential in the treatment of mental illness, we would have expected them
to be biased towards psychotherapy. Yet it is also plausible that in influential publications such
as randomized trials for depression, where a large number of contributors is usually involved,
the choice of the first author is strategic (e.g., giving visibility to a young researcher) and inter-
twined with other features of the trial. It is unclear how much leverage the first author of such
a trial would actually have in influencing trial outcomes or their presentation. We could specu-
late this result might also reflect other, unknown, particularities of trials where the first author
is a psychologist and that these particularities might be the ones responsible for results favoring
pharmacotherapy over psychotherapy. A similar argument probably holds for the result
regarding last author specialization. We note there were only 9 trials with a last author statisti-
cian/other technical and hence this finding might reflect some distinct features of this pool of
studies. It is also possible that both these borderline significant relationships reflect spurious
findings.
Limitations
There are number of limitations to our evaluation. We could not retrieve any previous litera-
ture attempting to evaluate author background from trial reports, and as such we could not
base our coding decisions on existent literature. To be able to classify extracted data, we were
compelled to resort to some simplifications and invariably sacrifice detail and granularity.
Evidently, arguments could be given for other coding choices. Information about author spe-
cialization was the result of extensive web searches and it is possible we have missed or misin-
terpreted some potential sources. We tried to be as conservative as possible and only classify
authors in one category when we were able to come across precise information about their aca-
demic education. This led to another limitation, namely that for a minority of authors we were
not able to recover this information. These authors were not included in the analyses and
could have potentially altered some of our results. The number of trials comparing psychother-
apy and pharmacotherapy for depression, while considerable, might have still been insufficient
for revealing more subtle effects of some author background variables. Finally, we only consid-
ered financial COI in relationship to the pharmaceutical industry, and not to psychotherapy
(e.g., royalties from manuals or books, payment from workshop, courses or training). Unfortu-
nately, even though several red flags have been raised regarding the relevance and need of dis-
closing and analyzing COI in regards to psychotherapy, the information necessary for its
assessment is still lacking[22], and there is still no consensus at to what should be considered
under this label. Apart from financial COIs, more intellectual COIs related to the practice
of psychotherapy, such the investigators’ commitment and faith in the intervention (i.e.,
researcher allegiance), or related possible self-confirmatory academic biases (i.e., authors of
previous positive trials would be committed to report more positive effects) might also have
biasing effects on the comparison between psychotherapy and pharmacotherapy.
Conclusions
Our study is, to our knowledge, the first to take on the painstaking task of describing and clas-
sifying the background of authors of reports of clinical trials for depression. We believe this
detailed overview of author background, as well as some of our coding choices, can be
resources for future research. In sum, our findings revealed some systematic trends regarding
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the background of authors conducting trials comparing psychotherapy and pharmacotherapy
for depression. The presence of statisticians, particularly in lead positions (last author) appears
to favor pharmacotherapy. There is a similar trend for having the first author psychologist as
compared to MD. None of these results were anticipated and might reflect spurious findings;
as such, speculating on their meaning might not be very relevant. It is worth pointing out these
differences are small, in some cases only borderline statistically significant and most likely not
clinically significant. Given that psychotherapy and pharmacotherapy were consistently shown
to be equally effective in the treatment of acute depression[1,2], it would have been surprising
to find anything other than subtle, small magnitude differences. Nevertheless, one factor that
does seem to override variables related to the specialization and affiliation of trial authors is
financial support from the pharmaceutical industry.
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